Vol 15, No 6 (2019):292-293

Nebivolol for improving endothelial dysfunction in cardiac syndrome-x; Is it ready for clinical use?

Alireza Fatahian



DOI: http://dx.doi.org/10.22122/arya.v15i6.1971

Abstract


-

Full Text:

PDF

References


Agrawal S, Mehta PK, Bairey Merz CN. Cardiac Syndrome X: Update. Heart Fail Clin 2016; 12(1): 141-56.

Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs 2015; 75(12): 1349-71.

Gao Y, Vanhoutte PM. Nebivolol: An endothelium-friendly selective beta1-adrenoceptor blocker. J Cardiovasc Pharmacol 2012; 59(1): 16-21.

Sen N, Tavil Y, Erdamar H, Yazici HU, Cakir E, Akgul EO, et al. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol Derg 2009; 9(5): 371-9.

Kayaalti F, Kalay N, Basar E, Mavili E, Duran M, Ozdogru I, et al. Effects of nebivolol therapy on endothelial functions in cardiac syndrome X. Heart Vessels 2010; 25(2): 92-6.

Erdamar H, Sen N, Tavil Y, Yazici HU, Turfan M, Poyraz F, et al. The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis 2009; 20(3): 238-4.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 4.0

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.